Nevertheless, some mature T cells could develop in the thymus, and these populated the periphery through homeostatic proliferation. a conformational change in the intracellular portion of CD3 ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency; INB-619, a next generation γδ ...

Building upon ARC101 as a foundation, Third Arc Bio continues to invest in its Synergy Platform to develop a pipeline of novel CD3 and CD28 targeting multispecifics to create transformational ... that ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...